Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial

Colomban et al.
JCO Clinical Cancer Informatics 2023 :7

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10

Colomban et al.
EBioMedicine . 2023 Mar;89:104477. doi: 10.1016/j.ebiom.2023.104477.

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study

You et al.
J Clin Oncol. 2022 Dec 1; 40(34): 3965–3974. doi: 10.1200/JCO.22.01207

CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study

You, B. et al.
Journal of Clinical Oncology 2023 41:1, 107-116

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era

You et al
British Journal of Cancer volume 127, pages79–83 (2022)

The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas

You, B et al.
Cancer Treatment Reviews, Volume 100, 102294

751P Survival prognostic and surrogate values of the early modeled CA-125 KELIM™ in newly diagnosed advanced ovarian cancer: Data from the GCIG meta-analysis group

Corbaux, P. et al.
Annals of Oncology, Volume 32, S744

847P The prognostic value of chemosensitivity, estimated by the modeled CA-125 KELIM™, in ovarian cancer patients treated with neo-adjuvant chemotherapy in the Netherlands

Van Wagensveld, L. et al.
Annals of Oncology, Volume 31, S633

CA-125 ELIMination rate constant K (KELIM™) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial

You, B et al.
Clin Cancer Res. 2020 Mar 24. pii: clincanres.0054.2020

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

Colomban, Tod, Leary, Ray-Coquard, Lortholary, Hardy-Bessard, Pfisterer, Du Bois, Kurzeder, Burges, Péron, Freyer, You B
Clin Cancer Res. 2019 Sep 1

Two prognostic populations of ovarian cancer patients defined by CA-125 modeled kinetic parameter KELIM™ (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/ MRC CTU/GCIG trials)

Benoit You, Olivier Colomban, Gilles Freyer, Alexandra Leary, Isabelle Laure Ray-Coquard, Alain Lortholary, Anne Claire Hardy Bessard, Jacobus Pfisterer, Andreas Du Bois, Christian Kurzeder, Alexander Burges, and Michel Tod
Journal of Clinical Oncology 2017 35:15_suppl, 5554-5554

The predictive value of the CA-125 modeled kinetic parameter KELIM™ is validated in 3 independent datasets (AGO-OVAR 7 & 9; ICON 7 AGO/GINECO/GCIG trials)

B.M. You O. Colomban M. Tod I.L. Ray-Coquard A. Lortholary A.C. Hardy-Bessard A. Du Bois J. Huober W. Meier C. Kurzeder
Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 857PD

A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment

You B, Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M, Colomban O
Annals of Oncology 25: 41–56, 2014

Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements

You B, Harvey R, Henin E, Mitchell H, Golfier F, Savage PM, Tod M, Wilbaux M, Freyer G, Seckl MJ.
Br J Cancer. 2013 May 14;108(9):1810-6.

Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias

You B, Pollet-Villard M, Fronton L, Labrousse C, Schott AM, Hajri T, Girard P, Freyer G, Tod M, Tranchand B, Colomban O, Ribba B, Raudrant D, Massardier J, Chabaud S, Golfier F.
Ann Oncol. 2010 Aug;21(8):1643-50.

Prognostic value of modeled PSA clearance on biochemical relapse free survival after radical prostatectomy

You B, Girard P, Paparel P, Freyer G, Ruffion A, Charrié A, Hénin E, Tod M, Perrin P.
Prostate. 2009 Sep 1;69(12):1325-33.